Aytu Biopharma, Inc: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 14, 2023 and accepted by EDGAR at Nov 14, 2023, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $22.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $7.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-07-01 to 2023-09-30 | $14.8m | us-gaap:GrossProfit |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $604.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-07-01 to 2023-09-30 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$8.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | −$1.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | −$1.48 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 5,482,037 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-07-01 to 2023-09-30 | −$211.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | $20.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $70.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $132.9m | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $65.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $100.7m | us-gaap:Liabilities |
| Long-term debt | At period end2023-09-30 | $15.0m | us-gaap:LongTermDebt |
| Short-term borrowings | At period end2023-09-30 | $1.2m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2023-09-30 | $32.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-23-019015. Last ingested by Listed: Oct 27, 2026, 16:32 ET. Listed shows no prices and gives no investment advice.